PT - JOURNAL ARTICLE AU - Lekh N. Dahal AU - Robert N. Barker AU - Frank J. Ward TI - The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus AID - 10.3899/jrheum.190678 DP - 2019 Dec 01 TA - The Journal of Rheumatology PG - jrheum.190678 4099 - http://www.jrheum.org/content/early/2019/11/25/jrheum.190678.short 4100 - http://www.jrheum.org/content/early/2019/11/25/jrheum.190678.full AB - Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by fluctuating levels of immune response hyperactivity, high serum titers of nucleic antigen-specific autoantibodies, and persistent production of type-I interferon (IFN)1. One route to controlling SLE has been to exploit the properties of T cell lymphocyte costimulation inhibitor (CTLA-4), a selective costimulation inhibitor, which suppresses autoantigen-specific T cell response intensity2.